Arvinas (ARVN) vs Rezolute (RZLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Arvinas (ARVN) has outperformed Rezolute (RZLT) over the past year, losing 23.0% versus a loss of 44.8%. Over five years, RZLT leads with a -26.8% price change compared with -91.2% for ARVN. Arvinas is the larger company by market cap ($492.9 million vs $471.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | RZLT |
|---|---|---|
| Share price | $7.64 | $4.87 |
| Market cap | $492.94M | $471.04M |
| 1-day change | +1.73% | +4.96% |
| YTD return | -36.68% | +106.36% |
| 1-year return | -22.97% | -44.85% |
| 5-year return | -91.18% | -26.77% |
| P/E ratio (TTM) | 29.38 | — |
| EPS (TTM) | $0.26 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.51 | $11.46 |
| 52-week low | $6.97 | $1.07 |
| Distance from 52-week high | -47.35% | -57.49% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +82.33% | +101.23% |
| Average volume | 788.21K | 1.48M |
| Shares outstanding | 64.52M | 96.72M |
| Employees | 246 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARVN has outperformed RZLT by 21.9 percentage points over the past year.
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
ARVN vs RZLT FAQ
Which is bigger, Arvinas or Rezolute?
Arvinas (ARVN) is larger, with a market capitalization of $492.94M compared with $471.04M for Rezolute (RZLT).
Which stock has performed better over the past year, ARVN or RZLT?
ARVN returned -22.97% over the past 12 months, compared with -44.85% for RZLT (price return, excluding dividends). Past performance does not predict future results.
Are Arvinas and Rezolute in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.